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In this cohort of unilateral retinoblastoma patients, children that presented with 
International Intraocular Retinoblastoma Classification Group B or C underwent 




Early diagnosis strategies and advances in retinoblastoma (Rb) management have 
resulted in nearly 100% survival. More attention should, therefore, be given to 
quality of life considerations. We aimed to quantify the number of examinations 
under anaesthesia (EUAs) in a cohort of Rb patients, as a measure of disease burden.  
Methods 
A retrospective analysis of unilateral Rb patients that presented to the London Rb 
service from 2006-2013, were treated and had long-term follow-up. Correlations of 
clinical variables to number of EUAs were investigated.  
Results 
A total of 107 Rb patients were included that presented at a mean age of 
26.51±22.68 months. The International Intraocular Retinoblastoma Classification 
(IIRC) was group B in 5 (5%), C in 13 (12%), D in 48 (45%) and E in 41 (38%) of the 
cases. Primary treatment was intravenous chemotherapy in 36 (34%) and 
enucleation in 71 (66%) of the cases. Mean number of EUAs was 20.67±6.62, 
12.52±6.23 and 11.15±6.91 for combined groups B/C, group D and group E patients 
(p<0.001). On analysis, early age of presentation and conservative treatments were 
found to significantly correlate with increased number of EUAs (p<0.001). Mean 
follow-up time was 74.42±25.16 months and no metastasis or death were reported.  
Conclusion 
Families should be counselled regarding the number of EUAs associated with the 
patient's IIRC group, with B/C eyes undergoing twice the number as compared to D/E 
eyes. For group D cases, where both enucleation and conservative therapy are valid 
options, treatment choice has a significant impact on the number of EUAs.  
INTRODUCTION 
Retinoblastoma (Rb), the most common primary intraocular malignancy of 
childhood,[1] is potentially a deadly metastatic cancer. With recent advances, 
however, in Rb diagnosis and management,[2] survival rate in high-income countries 
is at present estimated to be nearly 100%.[3] Consequently, while saving life remains 
the main goal in Rb management, more attention is being given to quality of life 
considerations in these young patients.  
Rb develops in the vast majority of cases before the age of 5 years. At presentation 
and throughout follow-up, especially in the early years, when the disease is active or 
can relapse, in order to perform a meticulous eye examination, patients are 
examined under anaesthesia (EUA). This allows for precise delivery of treatment 
without patient movement and for pain relief. It is common practice in Rb for 
children to undergo repeated EUAs, as needed, depending on various clinical factors 
and management decisions.[4] Patients’ families, however, are increasingly 
questioning the need for additional EUAs and commonly ask about the potential risk 
associated with general anaesthesia in infancy. The number of EUAs, in this sense, 
may be regarded as a measure of disease burden, on patients and their families, and 
the burden comprises many elements, including psychological, socioeconomic, and 
possibly physical.[5–9]  
In a previous study on International Intraocular Retinoblastoma Classification 
(IIRC)[10] group D cases, comparing patients that were treated conservatively to 
patients that underwent primary enucleation,[4] we found that the latter sub-cohort 
underwent on average 3-times less EUAs. To the best of our knowledge, there are no 
such other reports on any of the IIRC groups. Such information would be of added 
value when counselling patients and their families. The goal of the present study was 
to quantify the number of EUAs in a cohort of unilateral Rb cases from all IIRC 
groups, as well as to measure the total period of time (i.e. first to last) these patients 
had EUAs. In addition, we aimed to investigate possible associations to clinical 
variables and therapeutic interventions.  
METHODS 
This was a retrospective chart review of consecutive patients with unilateral Rb that 
presented to the London Retinoblastoma Service from 2006-2013, and were treated 
and monitored with long-term follow-up. Patients who presented with unilateral 
disease, but developed Rb in the fellow eye throughout follow-up were not included 
in this analysis. The study was approved by the Barts Health NHS Trust institutional 
review board (number 6622) in accordance with the tenets of the Declaration of 
Helsinki.  
Data retrieved from medical records included patients’ age at presentation, sex, 
laterality, presenting signs, clinical data at first examination, primary and additional 
treatments, genetic analysis results, data from operation notes, number and timing 
of EUAs, and follow-up clinical data until last examination.  
In this cohort, primary treatments included intravenous chemotherapy (IVC) or 
enucleation. Patients treated by means of IVC were given 6 courses of vincristine, 
etoposide and carboplatin (VEC), via a central line, approximately once every 3 
weeks. Adjuvant and/or salvage treatments used as per clinical scenario included 
transpupillary thermotherapy (TTT), cryotherapy, ruthenium plaque radiotherapy 
and intra-ophthalmic artery chemotherapy (IAC). Primary or secondary enucleation 
was performed as previously described.[4] Patients in which high-risk histopathology 
features were detected after enucleation were also treated with IVC to reduce the 
risk of systemic spread.[11]  
Examinations, all focal treatments and central line insertion and removal for VEC 
administration were performed under general anaesthesia. For general anaesthesia, 
the majority of patients had a gas induction with sevoflurane (up to 8%) in oxygen 
and nitrous oxide. Older children or children with indwelling lines were induced 
intravenously with propofol (titrated up to 4mg/kg). Unless there was a 
contraindication, the airways of children over 5 months of age were managed with a 
laryngeal mask. The trachea of younger children was intubated. Anaesthesia was 
maintained with sevoflurane (0.5 – 4% titrated according to response) in oxygen and 
nitrous oxide.  
In patients with active disease, tumour response to treatment and need for further 
intervention dictated the timing of the next EUA. In treated patients with tumour/s 
under control, the frequency of screening EUAs was dictated by the patient's age 
and genetic status (i.e. germline vs non-germline). Patients with known family 
history of Rb and/or patients with multifocal disease were considered to be germline 
cases, hence were examined more often than patients with no family history or 
patients with unifocal disease. All study patients were referred for RB1 genetic 
testing. Peripheral blood samples were collected from all new patients and fresh 
tumour samples from all enucleated eyes. Genetic testing employed a variety of 
methods to cover all types of RB1 mutations.[12,13] According to the RB1 mutation 
analysis results, the treating clinician titrated the frequency of EUAs. At around the 
age of 5 years, depending on the patient's cooperation and after at least one year of 
no active disease, an awake examination was attempted.  
Statistical Analysis and Definitions 
All calculations were performed using Microsoft Excel 2013 software (Microsoft 
Corporation, Redmond, WA) and SPSS software version 17.0 (SPSS, Inc., Chicago, IL).  
Number of EUAs consisted of all occasions in which a child was clinically evaluated or 
treated under general anaesthesia. For analysis, IIRC groups B and C were combined 
as both represented a small proportion of the entire cohort, which comprised mainly 
of patients with group D and E Rb. Correlations to number of EUAs and to the time 
interval from presentation to last EUA was performed via univariate analysis using 
Fisher's Exact Test and T-Test, for categorical and continuous variables, respectively. 
Variables found significant (P≤0.05) on univariate analysis were further evaluated 
using multivariate analysis (Stepwise Linear Regression).  
RESULTS 
The study cohort comprised of 107 patients (107 eyes). Of these, 59 (55%) were 
males and in 58 (54%), the right eye was involved. The IIRC was group B in 5 (5%) 
cases, C in 13 (12%), D in 48 (45%) and E in 41 (38%) of the cases, and AJCC[14] 
primary tumour site was cT1b in 5 (5%) cases, cT2a in 16 (15%), cT2b in 47 (44%), 
cT3b in 13 (12%), cT3c in 18 (17%) and cT3d in 8 (7%) of the cases. There were no 
cases of IIRC group A in this cohort. Of the study cohort, 22 (21%) patients had 
germline disease, 2 (2%) of which had positive family history of Rb. The mean (±SD) 
age of presentation was 26.51±22.68 months and mean interval from presentation 
to genetic analysis results was 3.97±2.53 months.  
Primary treatment was IVC in 36 (34%) and enucleation in 71 (66%) of the cases. Of 
the children with Group D and E Rb, 31 (65%) and 40 (98%), respectively, underwent 
primary enucleation, whereas all group B and C, 17 (35%) of the group D cases and 1 
(2%) group E case were treated initially by means of IVC. In the primary IVC group, 
secondary IAC was performed in 8 (22%, 1-6 procedures) patients, TTT in 16 (44%, 1-
19 treatment sessions), cryotherapy in 18 (50%, 1-14 treatment sessions) and 
secondary enucleation in 11 (31%). Of all enucleated patients (i.e. primary and 
secondary procedures; n=82), in 20 (24%), high-risk histopathology features were 
found on histopathology assessment, necessitating adjuvant IVC, and 3 (2%) 
underwent an implant repair procedure due to implant exposure. Mean follow-up 
time was 74.42±25.16 months and mean age at last visit was 100.93±33.29 months. 
All patients remained with unilateral disease throughout follow-up, none was 
diagnosed with metastatic disease and all were alive at final visit.  
For the whole cohort, mean number of EUAs was 13.36±7.32 and mean time from 
presentation to last EUA was 31.27±14.75 months (Figures 1 and 2). All patients at 
last visit were examined awake or referred for an awake examination. Investigating 
the different IIRC groups, mean number of EUAs was 20.67±6.62 for combined groups 
B+C, 12.52±6.23 for group D and 11.15±6.91 for group E patients (p<0.001). For the interval 
from presentation to last EUA, the mean time was 40.55±8.03 months for combined groups 
B+C, 30.60±14.45 months for group D and 27.98±14.75 months for group E (p=0.009). Age of 
presentation of combined groups B+C patients was 14.78±13.62 months whereas that of 
groups D and E patients was 29.24±25.87 and 28.46±20.58 months, respectively. The 
difference showed a trend that was non-significant (p=0.053).  
Evaluating clinical correlations with number of EUAs (Table 1), parameters that were found 
to reach statistical significance were age of presentation (inversely) and type of initial 
treatment (IVC associated with more EUAs; p<0.001 for both). Parameters that were found 
to significantly correlate to the time interval from presentation to last EUA (Table 1) were 
the time interval from presentation to genetic analysis results (direct correlation; p=0.013), 
age at presentation and initial treatment (p<0.001). On multivariate analysis (stepwise linear 
regression, (R2=0.561)), initial treatment with IVC (B=10.181, 95% confidence interval (CI) for 
B: 8.173 - 12.188) and age of presentation (B=-0.087, 95% CI for B: (-0.129) – (-0.045)) were 
found to be significant factors (p<0.001) predicting the number of EUAs. For the time 
interval from presentation to last EUA, the following parameters were found on multivariate 
analysis (stepwise linear regression, (R2=0.486)) to be significant predicting factors: primary 
treatment with IVC (B=8.419, 95% CI for B: 3.844-12.994, p<0.001), age of presentation (B=-
0.36, 95% CI for B: (-0.455) – (-0.264), p<0.001) and time interval to genetic tests results 
(B=1.444, 95% CI for B: 0.593-2.294, p=0.001).  
Table 1. number of examinations under anesthesia and time interval from presentation to last 
examinations under anesthesia in 107 unilateral retinoblastoma patients: univariate analysis.  
  Number of EUAs Presentation-last EUA (months) 
  Mean (St. Dev) P-value Mean ± St. Dev P-value 
Age of presentation*  26.51 (22.68) <0.001 26.51 (22.68) <0.001 
Sex Male 13.42 (7.56) 0.926 30.07 (15.82) 0.351 
 Female 13.29 (7.10) 32.75 (13.33) 
Laterality Right 12.12 (5.69) 0.055 29.51 (13.62) 0.179 
 Left 14.84 (8.71) 33.36 (15.87) 
IIRC** A NA <0.001 NA 0.009 
 B+C 20.67 (6.62) 40.55 (8.03) 
 D 12.52 (6.23) 30.60 (14.45) 
 E 11.15 (6.91) 27.98 (15.92) 
Germline Yes 14.91 (6.93) 0.269 35.53 (15.36) 0.129 
 No 12.96 (7.40) 30.17 (14.48) 
Time to genetic results*  3.97 (2.53) 0.328 3.97 (2.53) 0.013 
Initial treatment IVC 20.53 (7.52) <0.001 38.21 (12.88) <0.001 
 Enucleation  9.73 (3.62)  27.76 (14.46)  
* continuous variables (Fisher exact test).  
** Analysis of variance (between groups).  
EUA - examinations under anesthesia, IIRC – International Intraocular Retinoblastoma Classification, NA – 
non-applicable, IVC – intravenous chemotherapy 
 
Sub-analysis of the primary IVC-treated patients (n=36, Table 2), on multivariate analysis 
(stepwise linear regression, R2=0.648), the following parameters were found to be significant 
predictors of number of EUAs: cryotherapy (B=4.394, 95% CI for B: 0.753-8.035, p=0.02), TTT 
(B=6.308, 95% CI for B: 2.806-9.811, p=0.001), IAC (B=9.23, 95% CI for B: 4.645-13.814, 
p<0.001) and age of presentation (B=-0.086, 95% CI for B: (-0.149) - (0.023), p=0.009). On 
multivariate analysis (stepwise linear regression, R2=0.190) of parameters that correlate with 
the time interval from presentation to last EUA, only age of presentation was found to be a 
significant factor (B=-0.193, 95% CI for B: (-0.333) - (0.054), p=0.008).  
Table 2. number of examinations under anesthesia and time interval from presentation to last 
examinations under anesthesia in 36 unilateral retinoblastoma patients treated by intravenous 
chemotherapy: univariate analysis.  
  Number of EUAs Presentation-last EUA (months) 
  Mean (St. Dev) P-value Mean ± St. Dev P-value 
Age of presentation*  25.24 (23.69) 0.435 25.24 (23.69) 0.008 
Sex Male 21.63 (6.94) 0.359 36.82 (14.65) 0.503 
 Female 19.29 (8.15) 39.76 (10.81) 
Laterality Right 18.40 (6.38) 0.154 32.57 (12.40) 0.024 
 Left 22.05 (8.03) 42.24 (11.92) 
IIRC** A NA <0.001 NA 0.057 
 B+C 20.67 (6.62) 40.55 (8.03) 
 D 18.82 (5.48) 34.33 (15.39) 
 E 47.00 62.07 
Germline Yes 20.40 (5.17) 0.951 41.65 (9.64) 0.129 
 No 20.58 (8.33) 36.89 (13.87) 
Time to genetic results*  4.31 (2.74) 0.355 4.31 (2.74) 0.071 
IAC Yes 26.38 (10.30) 0.01 35.18 (14.19) 0.459 
 No 18.86 (5.72)  39.08 (12.63)  
Plaque brachytherapy Yes 24.75 (5.6) 0.071 36.74 (7.99) 0.719 
 No 19.32 (7.64)  38.63 (14.06)  
TTT Yes 24.69 (8.30) 0.002 39.21 (10.30) 0.684 
 No 17.20 (4.84)  37.41 (14.85)  
Cryotherapy Yes 24.83 (7.81) <0.001 38.46 (10.26) 0.911 
 No 16.22 (4.01)  38.00 (15.37)  
* continuous variables (Fisher exact test).  
** Analysis of variance (between groups).  
EUA - examinations under anesthesia, IIRC – International Intraocular Retinoblastoma Classification, NA – 
non-applicable, IAC – intra-arterial chemotherapy, TTT – transpupillary thermotherapy 
 
DISCUSSION 
Patients with unilateral Rb in the present cohort underwent on average 13 EUAs and 
for an average period of less than 3 years until they were examined and started to be 
monitored awake. These results, however, differed, depending on the disease group 
at presentation. Patients diagnosed at an early stage, i.e. IIRC groups B and C, 
underwent significantly more EUAs (x1.8) and for a longer period of time (x1.4), 
compared to advanced intraocular Rb (IIRC groups D and E). Comparing IIRC groups B 
and C to group E, the 2 main differences were the early age of presentation of the 
prior sub-cohort and the primary treatment used, and indeed, these 2 variables were 
found to be the only predicting factors on multivariate analysis of number of EUAs. 
While unilateral IIRC groups B and C are commonly preserved, with high success 
rate,[15] and group E eyes undergo primary enucleation in most practices, there is 
no consensus regarding the preferred management of unilateral group D cases. In 
the present study, 65% of patients with group D eyes underwent primary 
enucleation and in 35% conservative treatment was first attempted. There are many 
factors to be considered when deciding on a treatment strategy for Rb. Patients' 
families need also to be aware of the difference in number of EUAs in case 
conservative treatment is chosen over primary enucleation (x2.1 in case of IVC, for 
all IIRC groups), and this consideration is relevant especially in case of IIRC group D, 
as we showed in the present study and in a previous one.[4] 
Evaluating the total period of time patients in this cohort had EUAs, the time lag 
from presentation to the point at which genetic results were available for the 
treating clinicians was found to significantly correlate (in addition to age of 
presentation and primary treatment type). It is estimated that up to 18% of 
unilateral Rb cases are germline (i.e. carry one RB1 mutation in their constitutional 
cells).[16] Precise analysis and identification of the RB1 mutation is crucial, especially 
in unilateral-presenting cases, and was shown to enhance the quality of 
management of affected patient, as well as of their relatives.[17,18] Results of the 
present study show that having the analysis results available in a timely manner is 
also important to shorten the total period of time patients undergo EUAs.  
On sub-analysis of the primary IVC group, that is all group B and C, some of the 
group D cases and a single group E case, number of EUAs and the total time patients 
had EUAs, again, correlated with age of presentation, the prior also with secondary 
treatments, including cryotherapy, TTT and IAC. Age is a given parameter, known at 
presentation, hence can be used in this context as a predicting factor associated with 
EUAs (number and length). Secondary treatments, however, in case of 
conservatively treated patients, reflect active disease (in contrast to screening EUAs). 
In addition, the need for secondary treatments is obviously not known at 
presentation, hence is less useful to serving as a predicting factor in this context.  
This was a retrospective study; hence its inherent limitations relate to data collection 
and randomization. Nevertheless, we were able to collect detailed data from medical 
charts on all 107 patients and eyes, including all EUAs and treatments performed, as 
shown in figures 1 and 2. Most unilateral Rb cases (>80%) presented with group D or 
E, and in this sense the cohort presented herein is considerably large. There were no 
unilateral group A cases in this cohort, however, and only a few group B and C cases, 
necessitating us to combine the two latter sub-cohorts for analysis. Larger-cohort 
studies are required to better characterize, in terms of number and length of EUAs, 
cases that are diagnosed with early phase disease. The time under anaesthesia was 
difficult to quantify in this retrospective study as in many charts, especially in the 
early study years, these data were missing, but it would be an important factor in 
future prospective studies. In this respect, number of EUAs is a much clearer parameter 
to relate to, as compared to the time under anaesthesia. Last but not least, the results 
reported in the present study reflect the management algorithm used in the London 
Rb service at that particular time period. They should be carefully interpreted as 
treatment algorithms are rapidly changing with the use of first line IAC and 
secondary intravitreal chemotherapy to salvage eyes that would have previously 
been enucleated. Nevertheless, given that there are no studies on this subject, this 
and the previous report focusing on IIRC group D cases, can serve as a benchmark for 
future work in this area. In this sense, it would be interesting to investigate and 
compare the required number of EUAs following primary IAC.[19]  
In summary, in this cohort, patients that presented with unilateral IIRC group B or C 
underwent on average 21 EUAs until transferred to awake examinations. In contrast, 
patients with advanced unilateral disease, presenting with IIRC group D or E, 
underwent in average only 12 EUAs until seen awake. Early age of presentation and 
conservative primary treatment were found to be risk factors for more EUAs and for 
a longer period of time. The latter variable was also dependent on the time lag from 
presentation to genetic analysis being available. These data are valuable additions 
when consulting patients' families.  
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LEGEND 
Figure 1 – detailed map of examinations under anesthesia and treatments in 36 
patients with unilateral retinoblastoma treated initially with intravenous 
chemotherapy. EUA - examination under anesthesia; IVC – intravenous 
chemotherapy; TTT – transpupillary thermotherapy; IAC – intra-arterial 
chemotherapy. On Y axis: G – germline, NG – non-germline, F – familial 
retinoblastoma, NF – non-familial retinoblastoma, B-E – International Intraocular 
Retinoblastoma Classification.  
 
Figure 2 – detailed map of examinations under anesthesia and treatments in 71 
patients with unilateral retinoblastoma treated initially by enucleation. EUA - 
examination under anesthesia; IVC – intravenous chemotherapy. On Y axis: G – 
germline, NG – non-germline, F – familial retinoblastoma, NF – non-familial 
retinoblastoma, D-E – International Intraocular Retinoblastoma Classification.  
 
 


